Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.

Abstract

In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively).

Keywords: NDM; carbapenem resistance; cefiderocol; eradication; metallo-beta-lactamase.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Cefiderocol
  • Cephalosporins* / pharmacology
  • Cephalosporins* / therapeutic use
  • Gram-Negative Bacteria
  • Humans
  • Meropenem / pharmacology
  • Meropenem / therapeutic use
  • Microbial Sensitivity Tests
  • beta-Lactamases

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactamases
  • Meropenem